Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.40 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.34 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.34 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.34 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.34 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.34 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.34 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.34 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29687780 | 1.00 | ALDH1A1 (0.40) | ALDH1A1ELANELMNAGLACYP1A2 | |
| SCHEMBL739469 | 0.98 | ELANE (0.41) | ALDH1A1ELANELMNAGLACYP1A2 | |
| SCHEMBL6680955 | 0.82 | GAA (0.46) | ALDH1A1LMNAGLACYP1A2CYP3A4 | |
| SCHEMBL3527315 | 0.82 | HSD11B1 (0.47) | ALDH1A1ELANELMNACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL4611270 | 0.81 | ALDH1A1 (0.40) | ALDH1A1LMNAGLACYP1A2CYP3A4 | |
| SCHEMBL731096 | 0.80 | CA2 (0.48) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL5140208 | 0.80 | L3MBTL1 (0.40) | ALDH1A1LMNAGLACYP1A2CYP3A4 | |
| SCHEMBL14008998 | 0.78 | CYP1A2 (0.38) | ALDH1A1LMNAGLACYP1A2CYP3A4 | |
| SCHEMBL2517262 | 0.78 | MYC (0.42) | ALDH1A1LMNAGLACYP1A2CYP3A4 | |
| SCHEMBL4598967 | 0.77 | PSIP1 (0.42) | ALDH1A1LMNAGLACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4244378-A1 | METHOD FOR DETECTING NUCLEIC ACIDS IN A BIOLOGICAL SAMPLE | Innovative Diagnostics (FR) | 2023-09-20 | — | — | EP | claimed |
| WO-2022101583-A1 | METHOD FOR DETECTING NUCLEIC ACIDS IN A BIOLOGICAL SAMPLE | INNOVATIVE DIAGNOSTICS GENETICS (FR) | 2022-05-19 | — | — | WO | claimed |
| US-7972829-B2 | Process for producing transglutaminase | AJINOMOTO CO., INC. (JP) | 2011-07-05 | — | — | US | claimed |
| US-20100297729-A1 | PROCESS FOR PRODUCING TRANSGLUTAMINASE | AJINOMOTO CO., INC (JP) | 2010-11-25 | — | — | US | claimed |
| US-20030082746-A1 | Process for producing transglutaminase | AJINOMOTO CO. INC (JP) | 2003-05-01 | — | — | US | claimed |
| EP-1219713-A1 | PROCESS FOR PRODUCING TRANSGLUTAMINASE | Ajinomoto Co., Inc. (JP) | 2002-07-03 | — | — | EP | claimed |
| EP-4244378-A1 | METHOD FOR DETECTING NUCLEIC ACIDS IN A BIOLOGICAL SAMPLE | Innovative Diagnostics (FR) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022101583-A1 | METHOD FOR DETECTING NUCLEIC ACIDS IN A BIOLOGICAL SAMPLE | INNOVATIVE DIAGNOSTICS GENETICS (FR) | 2022-05-19 | — | — | WO | disclosed |
| US-8425914-B2 | Methods for enhanced somatostatin immunogenicity in the treatment of obesity | BRAASCH BIOTECH LLC (US) | 2013-04-23 | — | — | US | disclosed |
| EP-1219713-B1 | PROCESS FOR PRODUCING TRANSGLUTAMINASE | AJINOMOTO KK (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20110195080-A1 | Compositions and Methods for Enhanced Somatostatin Immunogenicity in the Treatment of Growth Hormone and Insulin-Like Growth Factor One Deficiency | BRAASCH BIOTECH LLC (US) | 2011-08-11 | — | — | US | disclosed |
| US-7972829-B2 | Process for producing transglutaminase | AJINOMOTO CO., INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100297729-A1 | PROCESS FOR PRODUCING TRANSGLUTAMINASE | AJINOMOTO CO., INC (JP) | 2010-11-25 | — | — | US | disclosed |
| US-7723067-B2 | Process for producing transglutaminase | AJINOMOTO CO., INC. (JP) | 2010-05-25 | — | — | US | disclosed |
| US-20030082746-A1 | Process for producing transglutaminase | AJINOMOTO CO. INC (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1219713-A1 | PROCESS FOR PRODUCING TRANSGLUTAMINASE | Ajinomoto Co., Inc. (JP) | 2002-07-03 | — | — | EP | disclosed |